Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Discovers Large Near Surface EM Conductor SE of Cam Copper Mine (click to learn more) Xcyte Digital Corp. Releases "Xperience" Subscription Service (click to learn more) Star Diamond: High Modelled Diamond Prices and High Proportions of Type IIa Diamonds (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Nuvation Bio Inc NUVB

Healthcare
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC... see more

Recent & Breaking News (NYSE:NUVB)

Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update

Business Wire 2 days ago

Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Business Wire April 24, 2024

Nuvation Bio Completes Acquisition of AnHeart Therapeutics

Business Wire April 10, 2024

Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer

Business Wire March 28, 2024

Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction

Business Wire March 25, 2024

Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors

Business Wire March 14, 2024

Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Business Wire February 29, 2024

Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors

Business Wire January 8, 2024

Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors

Business Wire January 8, 2024

Nuvation Bio Announces Departure of Chief Financial Officer

Business Wire November 13, 2023

Nuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

Business Wire November 2, 2023

Nuvation Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Business Wire August 3, 2023

Nuvation Bio Announces Formation of Oncology-Focused Scientific Advisory Board

Business Wire June 1, 2023

Nuvation Bio Reports First Quarter 2023 Financial Results and Provides Business Update

Business Wire May 4, 2023

Nuvation Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Business Wire March 15, 2023

Nuvation Bio Doses First Patient in Phase 1b Combination Study of NUV-868

Business Wire December 19, 2022

Nuvation Bio Reports Third Quarter 2022 Financial Results and Provides Business Update

Business Wire November 3, 2022

ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox

GlobeNewswire August 11, 2022

Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update

Business Wire August 4, 2022

Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program

Business Wire August 1, 2022